1-3 of 3
Yi Hu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Tao Jiang, Qiqi Jin, Jiahao Wang, Fengying Wu, Jian Chen, Gongyan Chen, Yunchao Huang, Jianhua Chen, Ying Cheng, QiMing Wang, Yueyin Pan, Jianying Zhou, Jianhua Shi, Xingxiang Xu, LiZhu Lin, Wei Zhang, Yiping Zhang, Yunpeng Liu, Yong Fang, Jifeng Feng, Zhehai Wang, Sheng Hu, Jian Fang, Yongqian Shu, Jiuwei Cui, Yi Hu, Wenxiu Yao, Xingya Li, Xiaoyan Lin, Rui Wang, Yongsheng Wang, Wei Shi, Gaohua Feng, Jun Ni, Beibei Mao, Dandan Ren, Huaibo Sun, Henghui Zhang, Luonan Chen, Caicun Zhou, Shengxiang Ren
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4830–4843.
https://doi.org/10.1158/1078-0432.CCR-23-0604
Published: 01 December 2023
View article titled, HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer
Open the PDF for HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03

Xinan Sheng, Haige Chen, Bin Hu, Xudong Yao, Ziling Liu, Xin Yao, Hongqian Guo, Yi Hu, Zhigang Ji, Hong Luo, Benkang Shi, Jiyan Liu, Jin Wu, FangJian Zhou, Zhisong He, Jinhai Fan, Weifeng Wang, Hui Feng, Sheng Yao, Patricia Keegan, Yiran Huang, Jun Guo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 489–497.
https://doi.org/10.1158/1078-0432.CCR-21-2210
Published: 01 February 2022
View article titled, Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Open the PDF for Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03 in another window
Includes: Supplementary data
Journal Articles

Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk

Zhe-Yi Hu, Qi Yu, Qi Pei, Cheng Guo
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (15): 3832–3842.
https://doi.org/10.1158/1078-0432.CCR-10-1122
Published: 28 July 2010
View article titled, Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk
Open the PDF for Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk in another window
Includes: Supplementary data